-
Three healthcare stocks I'm buying: Mako, ResMed and Centene
Monday, February 13, 2012 - 3:46amAuthor: Bob Freedland Covestor model: Healthcare The Healthcare Model had a relatively flat month in January, as this group of stocks underperformed the S&P 500. I continue to work to identify the strongest collection of stocks in this evolving area of medical care and related industries....
Read More >> -
UPDATE: Citigroup Downgrades Masimo Corporation to Sell
Friday, February 10, 2012 - 12:10pmCitigroup lowers its rating on Masimo Corporation (NASDAQ: MASI) to Sell from Neutral and lowers its price target to $20 from $21 on utilization challenges. Citigroup says, "2012 is unlikely to get easier for MASI after a tough 2011 where we saw further margin erosion and limited technology...
Read More >> -
UPDATE: Goldman Sachs Raises PT to $38 on MAKO Surgical, Maintains Buy
Tuesday, January 17, 2012 - 10:37amGoldman Sachs reiterates its Buy rating on MAKO Surgical (NASDAQ: MAKO) and raises its price target to $38 from $36 on higher estimates following fourth quarter pre-announcement from the company. Goldman Sachs notes, "4Q results should allay concerns regarding average selling prices (ASPs) in...
Read More >> -
Morgan Keegan Maintains Outperform, $26 Target on Masimo Corporation
Tuesday, January 17, 2012 - 8:05amMorgan Keegan reiterates its Outperform rating and $26 target price on Masimo Corporation (NASDAQ: MASI), reflecting a still-favorable risk/reward ratio for the company. Morgan Keegan says, "Masimo's 2011 stock underperformance was driven by issues that negatively impacted financial results,...
Read More >> -
UPDATE: Brean Murray Carret Maintains Buy, Lowers PT to $24 on Masimo Corporation
Friday, January 13, 2012 - 10:32amBrean Murray Carret maintains its rating of Buy on Masimo Corporation (NASDAQ: MASI) and lowers its price target to $24 from $27 as bar seems low for Q4. Brean Murray Carret says, "After several miscues during 2011, management guided Q4 to assume only 10% growth, which reflected a very cautious...
Read More >> -
Masimo Announces FDA Clearance and Full Market Release of the New Pronto-7 for Noninvasive Total Hemoglobin Spot-Check Measurement
Monday, January 9, 2012 - 12:24pmMasimo (NASDAQ: MASI) today announced FDA 510(k) clearance and full market commercial launch of the Masimo Pronto-7®—a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index.
Read More >> -
Notable Call Options Activity in MAKO Surgical
Monday, January 9, 2012 - 11:25amShares of MAKO Surgical (NASDAQ: MAKO) are higher on the session by 9.28%, currently trading at $31.45. The stock has been moving largely higher over the past five weeks and is currently trading above the 50-day moving average. Options traders are focusing on calls today. The strike seeing the...
Read More >> -
MAKO Surgical Corp. Expects it Will Sell 56-62 Rio Systems in 2012
Monday, January 9, 2012 - 7:32amMAKO Surgical Corp. (Nasdaq: MAKO) today announced its selected operating results for its fourth quarter and for the year ended December 31, 2011 and provided 2012 annual guidance in anticipation of its business update presentation at the 30th Annual J.P. Morgan Healthcare Conference at the Westin...
Read More >> -
MAKO Surgical Surging 11% After Upgrade
Tuesday, January 3, 2012 - 12:20pmShares of MAKO Surgical (NASDAQ: MAKO) are having much strength in early trading today. At one point, MAKO was up over 13%. Boutique firm, Summer Street, upgraded MAKO to a Buy, from a Neutral rating. Currently, shares of MAKO Surgical are trading over 11% higher at $28.19.
Read More >> -
Summer Street Upgrades MAKO Surgical to Buy
Tuesday, January 3, 2012 - 9:57amSummer Street has upgraded MAKO Surgical (NASDAQ: MAKO) from Neutral to Buy.
Read More >>
